TBRG vs TOI

TBRG exhibits a strong operational turnaround indicated by a Piotroski F-Score of 7/9, yet it faces a severe valuation disconnect. While the current price of $23.18 trades at a massive premium to the Graham Number ($8.94) and Intrinsic Value ($2.03), the Forward P/E of 7.92 and PEG of 0.28 suggest the market is pricing in an aggressive earnings explosion. The company's pivot to Revenue Cycle Management (RCM) is yielding significant EPS surprises, but thin profit margins and market saturation in the small-hospital segment remain critical headwinds.

The Oncology Institute (TOI) exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price/Book ratio of -22.14, indicating negative shareholders' equity. While the company shows impressive top-line revenue growth of 41.60% YoY, it remains unprofitable with negative operating and profit margins. There is a stark divergence between the 'Strong Buy' analyst consensus and the actual financial health and bearish insider selling patterns. The lack of a Graham Number or Altman Z-Score further underscores the company's distressed financial state.